Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2010

View Archived Issues

French scientists claim epipodophyllotoxin derivatives with antitumor activity

Janssen presents novel TRPM8 receptor antagonists

New urocortin III fragments with antidepressant/anxiolytic activity claimed by Hungarian scientists

Sequoia Pharmaceuticals discovers NS3/NS4A protease inhibitors for HCV infections

Hetero Research Foundation presents new SGLT inhibitors

Vitae Pharmaceuticals identifies novel beta-secretase inhibitors

Studies detail PEP-005 efficacy for actinic keratoses on head and nonhead areas

Phase III trial of magnesium sulfate in acute stroke currently recruiting participants

Phase III data on Cervarix for the prevention of HPV-associated cervical cancer disclosed

Korean scientists identify new dual PPAR-alpha/gamma activator

Trillium expands immunology pipeline and enters stem cell field

Pfizer discontinues phase III trial of figitumumab in NSCLC

Ipsen grants Rhythm worldwide license for two programs in metabolic disorders

Once-daily nemonoxacin meets primary endpoints in phase II trial in diabetic foot infection

FDA accepts for review Abbott's Lupron sNDA for prostate cancer

FDA approves Watson Pharmaceuticals' twice-yearly Trelstar formulation for prostate cancer

Manhattan and Ariston Pharmaceuticals complete merger

FDA approves 5-day dosing of Eisai's Dacogen for MDS

Pfizer reports on phase III Sutent trials in advanced breast cancer

Medivir's Xerclear cold sore therapy to be launched in Sweden

FDA grants orphan drug designation to Bayer HealthCare's ciprofloxacin dry powder inhaler

Progenics to advance oral methylnaltrexone into phase IIb/III trials in OIC

CBio achieves milestone under collaboration with Novo Nordisk

Acura and King report topline data on relative abuse potential Acurox

Neoprobe reports successful meeting with FDA on Lymphoseek phase III results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...